Montserrat, L., Carmen, C., Javier, M., et al. (2009) Randomized Trial Comparing Pegylated Interferon 2b Versus Pegylated Interferon 2a, Both Plus Ribavirin, to Treat Chronic Hepatitis C in Human Immunodeficiency Virus Patients. Hepatology, 49, 22-310.
https://doi.org/10.1002/hep.22598

has been cited by the following article:

• TITLE: Study of the Efficacy of Triple Therapy of Sofosbuvir, Pegylated INFalpha 2a and Ribavirin in Treatment of Chronic Hepatitis C Patients Genotype 4 with High Fibrosis

  AUTHORS: Alaa Aboud

  KEYWORDS: Chronic Hepatitis C, Sofosbuvir, Pegylated INF, Ribavirin

  JOURNAL NAME: Open Journal of Gastroenterology, Vol.7 No.1, January 11, 2017

  ABSTRACT: Purpose: The aim is evaluation of the efficacy of triple therapy of sofosbuvir, pegylated INFalpha 2a and ribavirin in treatment of chronic hepatitis C (CHC) patients genotype 4 who have high fibrosis. Materials and Methods: Fifty HCV patients with high fibrosis (F3 & F4) were included in the study. Results: SVR rate was 54%; non-responders rate was 12% and relapsers rate was 34%. When comparing SVR between F3 group patients and F4 group, it was 88% and 66% respectively, which means that SVR was higher in the F3 group. Conclusion: Triple therapy including pegylated INFalpha 2a is not an ideal therapy in treatment of CHC patients genotype 4 with cirrhosis because of low sustained virological response rates and high incidence of side effects.